{"id":69068,"date":"2026-04-28T11:47:08","date_gmt":"2026-04-28T11:47:08","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/69068\/"},"modified":"2026-04-28T11:47:08","modified_gmt":"2026-04-28T11:47:08","slug":"evrope-hrozi-nedostatek-leku-varuji-farmaceuticti-obri-zenou-brusel-k-soudu-kvuli-smernici","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/69068\/","title":{"rendered":"Evrop\u011b hroz\u00ed nedostatek l\u00e9k\u016f, varuj\u00ed farmaceuti\u010dt\u00ed ob\u0159i. \u017denou Brusel k soudu kv\u016fli sm\u011brnici"},"content":{"rendered":"<p>V\u00fdrobci generick\u00fdch l\u00e9k\u016f podali \u017ealobu k Evropsk\u00e9mu soudn\u00edmu dvoru ve snaze zablokovat kontroverzn\u00ed sm\u011brnici o \u010di\u0161t\u011bn\u00ed m\u011bstsk\u00fdch odpadn\u00edch vod. Podle v\u00fdrobc\u016f nov\u00fd syst\u00e9m roz\u0161\u00ed\u0159en\u00e9 odpov\u011bdnosti v\u00fdrobce fakticky znamen\u00e1 zaveden\u00ed dan\u011b z l\u00e9\u010den\u00ed, kter\u00e1 u kl\u00ed\u010dov\u00fdch medikament\u016f m\u016f\u017ee dos\u00e1hnout a\u017e stovek procent jejich prodejn\u00ed ceny. Pokud soud nezas\u00e1hne, hroz\u00ed podle organizace <a href=\"https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2026\/04\/Leading-manufacturers-appeal-in-proceedings-against-discriminatory-wastewater-fees-on-medicine-before-European-Court-of-Justice-PR-27042026.pdf\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Medicines For Europe<\/a> nevratn\u00e9 sta\u017een\u00ed n\u011bkter\u00fdch l\u00e9k\u016f z trhu. T\u00edm by do\u0161lo k ohro\u017een\u00ed \u017eivot\u016f milion\u016f pacient\u016f.<\/p>\n<p>Medicines for Europe, reprezentuj\u00edc\u00ed farmaceutick\u00e9 giganty jako Sandoz, Teva, Zentiva \u010di Stada, se rozhodlo pro radik\u00e1ln\u00ed pr\u00e1vn\u00ed krok pot\u00e9, co Soudn\u00ed dv\u016fr EU <a href=\"https:\/\/www.zdravotnickydenik.cz\/2026\/02\/soudni-dvur-eu-smernice-cisteni-vod\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">zam\u00edtl jejich p\u016fvodn\u00ed \u017ealobu z procesn\u00edch d\u016fvod\u016f<\/a>, ani\u017e by se zab\u00fdval v\u011bcnou podstatou probl\u00e9mu. J\u00e1drem sporu je sm\u011brnice o \u010di\u0161t\u011bn\u00ed m\u011bstsk\u00fdch odpadn\u00edch vod. Ta zav\u00e1d\u00ed povinnost v\u00fdrobc\u016f l\u00e9\u010div a kosmetiky financovat takzvan\u00e9 kvart\u00e9rn\u00ed \u010di\u0161t\u011bn\u00ed odpadn\u00edch vod zam\u011b\u0159en\u00e9 na mikropolutanty. V\u00fdrobci v\u0161ak upozor\u0148uj\u00ed, \u017ee Brusel pracoval s naprosto nere\u00e1ln\u00fdmi \u010d\u00edsly.<\/p>\n<p>Zat\u00edmco Evropsk\u00e1 komise (EK) odhaduje n\u00e1klady \u0159\u00e1dov\u011b ni\u017e\u0161\u00ed, ekonomick\u00e9 modely pr\u016fmyslu hovo\u0159\u00ed o zat\u00ed\u017een\u00ed a\u017e 11 miliard eur (268 miliard korun) ro\u010dn\u011b. Tento propastn\u00fd rozd\u00edl pramen\u00ed z \u00fadajn\u011b chybn\u00fdch dat o toxicit\u011b. Anal\u00fdzy zalo\u017een\u00e9 na datech Evropsk\u00e9 l\u00e9kov\u00e9 agentury (EMA) podle asociace ukazuj\u00ed, \u017ee sledovan\u00e9 molekuly tvo\u0159\u00ed m\u00e9n\u011b ne\u017e 1 % chemick\u00fdch rezidu\u00ed. Nikoliv 58 %, jak tvrd\u00ed EK.<\/p>\n<p>\u201eTento odvolac\u00ed proces je o zaji\u0161t\u011bn\u00ed toho, aby Evropa nevystavila pacienty riziku prost\u0159ednictv\u00edm \u0161patn\u011b navr\u017een\u00e9 legislativy. Pot\u0159ebujeme z\u00e1kony na ochranu \u017eivotn\u00edho prost\u0159ed\u00ed. Ty ale mus\u00ed b\u00fdt zalo\u017een\u00e9 na v\u011bd\u011b a j\u00edt ruku v ruce s prevenc\u00ed nedostatku l\u00e9k\u016f,\u201c uvedl Adrian van den Hoven, gener\u00e1ln\u00ed \u0159editel Medicines for Europe.<\/p>\n<p>Doplnil ho i Steffen Saltofte, gener\u00e1ln\u00ed \u0159editel spole\u010dnosti Zentiva a p\u0159edseda Medicines for Europe. \u201eGenerick\u00e1 l\u00e9\u010diva tvo\u0159\u00ed z\u00e1klad cenov\u011b dostupn\u00e9 zdravotn\u00ed p\u00e9\u010de v Evrop\u011b. Pokud jsou na z\u00e1kladn\u00ed l\u00e9ky uvalen\u00e9 nep\u0159im\u011b\u0159en\u00e9 n\u00e1klady, st\u00e1vaj\u00ed se jejich dod\u00e1vky ekonomicky neudr\u017eiteln\u00fdmi a d\u016fsledky nakonec zaplat\u00ed pacienti. Ochrana \u017eivotn\u00edho prost\u0159ed\u00ed a ve\u0159ejn\u00e9 zdrav\u00ed jdou ruku v ruce. Jedno by nem\u011blo b\u00fdt ob\u011btov\u00e1no ve prosp\u011bch druh\u00e9ho,\u201c sd\u011blil v tiskov\u00e9 zpr\u00e1v\u011b Zentivy.<\/p>\n<p>Na \u00fapravy a\u017e po zaveden\u00ed m\u016f\u017ee b\u00fdt pozd\u011b<\/p>\n<p>Dopady na konkr\u00e9tn\u00ed l\u00e9\u010diva jsou podle tiskov\u00e9 zpr\u00e1vy Medicines for Europe alarmuj\u00edc\u00ed. Nap\u0159\u00edklad u l\u00e9k\u016f na epilepsii, jako je levetiracetam, hroz\u00ed nav\u00fd\u0161en\u00ed n\u00e1klad\u016f o 322 %. To by jej u\u010dinilo pro d\u011btsk\u00e9 pacienty prakticky nedostupn\u00fdm. Je\u0161t\u011b drasti\u010dt\u011bj\u0161\u00ed je situace u metforminu, kter\u00fd u\u017e\u00edv\u00e1 16 milion\u016f diabetik\u016f v EU. Zde by poplatky mohly dos\u00e1hnout a\u017e 875 % hodnoty l\u00e9ku.<\/p>\n<p>V\u00fdrobci varuj\u00ed, \u017ee v segmentu generik, kde jsou mar\u017ee minim\u00e1ln\u00ed, je takov\u00e9 zat\u00ed\u017een\u00ed neudr\u017eiteln\u00e9. Firmy nebudou m\u00edt jinou mo\u017enost ne\u017e v\u00fdrobu ukon\u010dit, p\u0159i\u010dem\u017e p\u0159echod na alternativn\u00ed l\u00e9\u010dbu by nap\u0159\u00edklad v p\u0159\u00edpad\u011b diabetu mohl zv\u00fd\u0161it n\u00e1klady na zdravotn\u00ed p\u00e9\u010di a\u017e p\u011btadvacetkr\u00e1t.<\/p>\n<p>    Mohlo by v\u00e1s zaj\u00edmat<\/p>\n<p>        <a href=\"https:\/\/www.zdravotnickydenik.cz\/2026\/04\/stamiliony-pro-zodpovedne-vzp-fond-prevence\/\" class=\"relative block overflow-hidden rounded-lg group aspect-[3\/2] md:aspect-video min-w-[88px] sm:min-w-[175px] lg:min-w-[225px]\" aria-label=\"\u010d\u00edst v\u00edce\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n                        <img loading=\"lazy\" decoding=\"async\" width=\"417\" height=\"256\" src=\"https:\/\/www.europesays.com\/cz\/wp-content\/uploads\/2026\/04\/img-3181-417x256.jpg\" class=\"absolute object-cover w-full h-full group-hover:scale-105 transition-all\" alt=\"\"  \/><br \/>\n                        <\/a><\/p>\n<p>\u201eBez \u0159e\u0161en\u00ed hroz\u00ed preventivn\u00ed stahov\u00e1n\u00ed l\u00e9k\u016f z ob\u011bhu, omezen\u00ed dod\u00e1vek a zv\u00fd\u0161en\u00e1 nep\u0159edv\u00eddatelnost pro zdravotnick\u00e9 syst\u00e9my. Jak\u00e1koli korekce b\u011bhem implementace p\u0159ijde p\u0159\u00edli\u0161 pozd\u011b na to, aby zabr\u00e1nila v\u00fdznamn\u00e9mu po\u0161kozen\u00ed ve\u0159ejn\u00e9ho zdrav\u00ed,\u201c varuj\u00ed firmy.<\/p>\n<p>L\u00e9ky nelze jednodu\u0161e \u201ezezelenat\u201c<\/p>\n<p>Argument environment\u00e1ln\u00ed motivace sm\u011brnice nav\u00edc podle v\u00fdrobc\u016f generik nar\u00e1\u017e\u00ed na technologickou realitu farmaceutick\u00e9 v\u00fdroby. Argumentuj\u00ed, \u017ee na rozd\u00edl od jin\u00fdch odv\u011btv\u00ed nelze aktivn\u00ed slo\u017eky l\u00e9k\u016f jednodu\u0161e \u201ezezelenat\u201c nebo nahradit ekologi\u010dt\u011bj\u0161\u00ed variantou, ani\u017e by ztratily svou \u00fa\u010dinnost nebo vy\u017eadovaly miliardov\u00e9 investice do nov\u00fdch klinick\u00fdch studi\u00ed s nejist\u00fdm v\u00fdsledkem.<\/p>\n<p>U antibiotik, jako je ciprofloxacin, by nav\u00edc snaha o modifikaci mohla paradoxn\u011b v\u00e9st k nutnosti vy\u0161\u0161\u00edho d\u00e1vkov\u00e1n\u00ed, co\u017e by d\u00e1le urychlilo hrozbu antimikrobi\u00e1ln\u00ed rezistence.<\/p>\n<p>\u010cas na \u0159e\u0161en\u00ed se p\u0159itom ne\u00faprosn\u011b kr\u00e1t\u00ed. Poplatky pro rok 2029 se budou po\u010d\u00edtat z prodej\u016f v roce 2028, co\u017e znamen\u00e1, \u017ee farmaceutick\u00e9 firmy mus\u00ed \u010dinit nevratn\u00e1 rozhodnut\u00ed o pokra\u010dov\u00e1n\u00ed v\u00fdroby pro evropsk\u00fd trh u\u017e nyn\u00ed.<\/p>\n","protected":false},"excerpt":{"rendered":"V\u00fdrobci generick\u00fdch l\u00e9k\u016f podali \u017ealobu k Evropsk\u00e9mu soudn\u00edmu dvoru ve snaze zablokovat kontroverzn\u00ed sm\u011brnici o \u010di\u0161t\u011bn\u00ed m\u011bstsk\u00fdch odpadn\u00edch&hellip;\n","protected":false},"author":2,"featured_media":69069,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[373,109,108,106,17251,8487,1617,23069,23070,23071,23072,23073,23074],"class_list":{"0":"post-69068","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-evropa","8":"tag-eu","9":"tag-europa","10":"tag-europe","11":"tag-evropa","12":"tag-farmaceuticke-firmy","13":"tag-farmaceuticky-prumysl","14":"tag-leky","15":"tag-medicines-for-europe","16":"tag-sandoz","17":"tag-smernice-o-cisteni-odpadnich-vod","18":"tag-stada","19":"tag-teva","20":"tag-zentiva"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116482175503866327","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/69068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=69068"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/69068\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/69069"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=69068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=69068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=69068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}